Development trends of PD-1 drugs in domestic pharmaceutical enterprises: the number of applications for registration has reached 15
-
Last Update: 2017-07-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Sina pharmaceutical announced on July 10, 2017 that the recombinant anti PD-1 humanized monoclonal antibody injection developed by Fuhong Hanlin for solid tumor treatment was accepted by CFDA clinical trial registration review Fosun Pharmaceutical has invested about 33 million yuan in the research and development of the new drug As of July 10, 2017, a total of 15 domestic PD-1 / PD-L1 drugs have applied for clinical application, including 10 PD-1 monoclonal antibodies, 4 PD-L1 monoclonal antibodies and 1 PD-L1 single domain antibody PD1 / PD-L1 drugs and R & D stage declared by domestic enterprises
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
